Algorae Pharmaceuticals Limited Overview
Algorae Pharmaceuticals is an Australian micro-cap that has spent the past four years turning a dormant xenotransplantation biotech, Living Cell Technologies, into a self-described "AI-enabled pharmaceutical company" with two tracks.
The discovery track is built around AlgoraeOS, a proprietary deep-learning platform developed with the UNSW AI Institute and supported by CSIRO Data61. AlgoraeOS predicts synergistic drug combinations. Its candidates are fixed-dose combinations: AI-116 (donepezil plus cannabidiol) for dementia and AI-168 (beta-blocker plus cannabidiol) for cardiovascular disease. The legacy NTCELL encapsulated-cell implant for Parkinson's disease remains under review.
The commercial track is AlgoraeRx, which is building a licensed generic and specialty medicines business in Australia and New Zealand. It has partners in India (Sakar, Cadila, Dr. Reddy's, Zydus and Torrent) and a NSW Health hospital supply contract.
The company had no product revenue in FY2026 and remains reliant on equity raisings. It is an early-stage, high-optionality, high-execution-risk story trading at roughly A$26m market capitalisation.
Company's own description (FY2026 Annual Report)
The FY2026 directors' report describes Algorae as an AI-enabled pharmaceutical company operating a synergistic dual-track business that combines AI-driven drug discovery with pharmaceutical commercialisation.
Discovery: is built around AlgoraeOS, its proprietary AI drug-combination prediction platform, together with a therapeutic pipeline comprising AI-116 for dementia and AI-168 for cardiovascular disease.
Commercial activities: are conducted through the wholly owned subsidiary AlgoraeRx Pty Ltd. AlgoraeRx sources, licenses, registers and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels.
Management characterised FY2026 as "a year of transition", in which the group moved from a single-track R&D business to a dual-track model. No product revenue was recognised during the year.
Independent characterisation
In substance, Algorae today is three things.
(a) A small AI/computational biology research programme.
-
It is largely outsourced to UNSW (Master Research Agreement, total fee A$726,565) and to the Peter MacCallum Cancer Centre's Victorian Centre for Functional Genomics (VCFG) for wet-lab validation.
-
Its output is ranked lists of predicted drug-pair synergies, which the company intends to convert into patentable fixed-dose combinations, often repurposing off-patent drugs.
-
This is a capital-light "asset generation" model. Value creation depends on securing patent positions on combinations and then licensing or developing them.
(b) A start-up generic pharmaceutical sponsor/distributor (AlgoraeRx).
-
It in-licenses dossiers or finished products from Indian manufacturers.
-
It acts as Australian TGA sponsor, manages registration, pricing and reimbursement, and sells to hospitals, pharmacies and institutional buyers.
-
It is a low-margin, volume-driven, regulatory-execution business that could provide recurring revenue far sooner than the discovery track.
-
The first stock was received in FY2026: inventory of A$180,744 and a first Dr. Reddy's capecitabine shipment in January 2026.
(c) A legacy cell-therapy shell.
- This comprises NTCELL, Living Cell Technologies NZ, carried-forward tax losses of A$46.2m, and NZ R&D loss tax credits of A$1.78m that are contingently repayable.
Business and revenue model
| Dimension | Current state (FY2026) |
|---|---|
| Revenue model mix | 100% interest income (A$77,667). No product, service, subscription or licensing revenue recognised. |
| Expected near-term revenue source | Product sales by AlgoraeRx: generic oncology, cardiovascular, metabolic and specialty medicines. First NSW Health supply orders were expected in Q4 calendar 2026. |
| Longer-term revenue source | Out-licensing or partnering of AI-derived combination drug candidates and IP; potential platform collaborations (n/d). |
| Value chain position | Discovery: in-silico target and combination identification upstream of preclinical. Commercial: sponsor, regulatory holder and market-access layer between offshore manufacturers and ANZ wholesalers/hospitals. |
| Customer types | Public hospitals (NSW Health standing offer), pharmacies, institutional buyers, wholesalers; future pharma licensees for discovery assets. |
| End-markets | ANZ generic prescription medicines (oncology, cardiovascular, metabolic, injectables/specialty); dementia/Alzheimer's; cardiovascular disease; Parkinson's disease (legacy). |
| Geographic focus | Australia (predominant) and New Zealand |
Strategy
Stated strategy (FY2026 AR, paraphrased tenets)
-
Maintain a dynamic, innovative culture focused on emergent pharmaceutical development themes.
-
Expand the R&D project pipeline to diversify value-generating activities.
-
Build a diversified, multi-partner commercial portfolio of generic and specialty medicines and take products through TGA registration to market.
-
Collaborate with industry, CROs and universities.
-
Implement a robust IP strategy.
-
Ensure adequate funding for research, development and commercial activities.
The stated objective is value creation through clinically validated IP plus a recurring commercial revenue base.
FY2027 stated priorities
-
Progress TGA registration submissions across the licensed portfolio.
-
Commence supply under commercial agreements, including the NSW Health contract (first orders expected Q4 CY2026).
-
Complete the second Peter Mac/VCFG validation of AOS2 (full dataset within ~6 months of the March 2026 start).
-
Finalise the shortlist from the multi-anchor AOS2 prediction set.
Initiative register (last 24 months)
| Date | Initiative | Type | Detail |
|---|---|---|---|
| Jun 2025 | Commercial build-out | New business | CCO hire; AlgoraeRx established |
| Sep 2025 – May 2026 | Five manufacturer agreements | Partnerships | Sakar, Cadila, Dr. Reddy's, Zydus, Torrent |
| Nov 2025 | AOS2 launch | Platform investment | Benchmarked against DeepMind TxGemma |
| Nov–Dec 2025 | Loyalty Options Offer | Capital | 1-for-5 options at A$0.001 (exercise A$0.014, expiry Dec 2029); A$199k plus A$139k shortfall |
| Jan 2026 | ScotPac A$3.0m facility | Working capital | BBSY + 6.70%, 24 months, undrawn |
| Mar 2026 | Second Peter Mac programme | Validation | 24 combinations across 4 cancer lines |
| Apr 2026 | First TGA dossier accepted | Regulatory | A second dossier was accepted by the June quarter |
| May 2026 | Multi-anchor AOS2 | Pipeline | 18 anchors; >9m predictions |
| 23–29 Jun 2026 | AgenticScale.ai SOW (A$120k) and Sovereign AI Infrastructure launch partner | AI infrastructure | NVIDIA-based sovereign compute |
| Jul 2026 | NSW Health supply contract | Commercial | 3+1+1 years |
Cost programmes: none announced.
ESG commitments: none disclosed.
Medium-term financial targets: none formally guided. Implicit targets are embedded in performance-rights hurdles: A$10m, A$15m and A$25m revenue at ≥20% EBIT margin, and market capitalisation of A$75m–A$250m. These are incentive hurdles, not guidance.
Products & Services
No product has yet generated recognised revenue. Products are listed by track.
Discovery platform
| Offering | Description | Key specifications / capabilities | Target user | Version / year | Pricing |
|---|---|---|---|---|---|
| AlgoraeOS v1 (AOS1) | AI drug-combination synergy prediction platform | Used to select 21 CBD-partner drugs (plus 3 investigational) for validation; 96 preclinical assessments across 4 cancer cell lines (T98G, BT20, PANC1, 22Rv1); ~10,000 data points | Internal pipeline generation | Built 2023–2025 with UNSW | Internal; not sold |
| AlgoraeOS v2 (AOS2) | Uncertainty-aware deep-learning upgrade | See detail below | Internal; potential partners | Launched 10 Nov 2025 | Internal; n/d |
| AOS2 single-anchor programme (CBD) | CBD × >3,000 approved/investigational drugs × 170 cell lines | >500,000 combinations scored; 90 high-quality candidates; 24 selected for second Peter Mac validation | Internal | Dec 2025 | — |
| AOS2 multi-anchor programme | Extension to 18 additional anchor drugs | >9 million predictions; >478,000 passing initial thresholds; >6,000 combinations with multi-cell-line synergy; curation underway | Internal | 18 May 2026 | — |
AOS2 key specifications:
-
Trained on >5.5m unique inhibition records (~11m with augmentation).
-
Models the full dose–response surface.
-
Predicts Bliss, Loewe, HSA and ZIP synergy measures simultaneously.
-
Produces aleatoric and epistemic uncertainty estimates.
-
On the NCI-ALMANAC benchmark, ZIP MAE 2.89 and Loewe MAE 6.46. The comparison models scored ZIP 3.78 / Loewe 17.38 (Tx-LLM (M)) and ZIP 3.81 / Loewe 17.34 (TxGemma-27B-Predict).
Therapeutic pipeline (preclinical unless noted)
| Candidate | Composition / modality | Indication | Partner | Stage | IP |
|---|---|---|---|---|---|
| AI-116 | Fixed-dose combination of donepezil plus cannabidiol (CBD) | Dementia including Alzheimer's disease | — | Preclinical; no material new results announced in FY2026 | PCT application filed |
| AI-168 | Fixed-dose combination of a beta-blocker plus CBD | Cardiovascular disease (vascular cell dysfunction) | Victorian Heart Institute, Monash University | Preclinical; no material new results in FY2026 | PCT application filed |
| NTCELL | Alginate-coated capsule containing neonatal porcine choroid plexus cells (IMMUPEL immunoprotective coating) | Parkinson's disease | — | Legacy; Phase IIb completed historically; under strategic review led by CSO | Legacy encapsulation IP |
| LP-003 | Anti-obesity drug candidate | Obesity | — | Listed by Morningstar; not described in FY2026 AR | — |
| LC-002 | Migraine treatment candidate | Migraine | — | Listed by Morningstar; not described in FY2026 AR | — |
| 24 AI-generated oncology targets / combinations | AOS-derived combinations | Oncology (glioblastoma, rhabdomyosarcoma, melanoma, CML cell models in second Peter Mac programme) | Peter MacCallum Cancer Centre (VCFG) | In-vitro validation | Wholly owned (per company) |
Commercial portfolio — AlgoraeRx (ANZ generics and specialty)
| Partner | Agreement date | Scope | Products named | Status (FY2026 AR) |
|---|---|---|---|---|
| Sakar Healthcare Ltd (NSE: SAKAR) | 23 Sep 2025 (exclusive licence) | 5 generic oncology medicines, ANZ | n/d (aggregator cites initial ~A$10m annual addressable market) | Licence fee commitment US$110k, of which US$25k paid |
| Cadila Pharmaceuticals Ltd | Term sheet 20 Oct 2025; definitive Licence & Supply Agreement 9 Feb 2026 | 2 generics, cardiovascular/metabolic | — | TGA registration planning commenced; licence fee commitment A$45k |
| Dr. Reddy's Laboratories (NSE: DRREDDY; NYSE: RDY) | 27 Nov 2025 (distribution) | Supply into Australia | Capecitabine 500 mg tablets (chemotherapy) | First shipment January 2026 |
| Zydus Lifesciences (NSE: ZYDUSLIFE) | 28 Apr 2026 (exclusive commercial and licensing) | 10 injectable, oral and specialty products, ANZ | — | Joint prioritisation; subject to TGA approvals |
| Torrent Pharmaceuticals (NSE: TORNTPHARM) | 6 May 2026 (Licence & Supply) | 2 generic prescription molecules, phased | — | Phase 1 uses existing or cloned registrations; Phase 2 requires new TGA registrations |
| NSW Health (customer) | 1 Jul 2026 (standing offer) | Supply of one awarded product to NSW public hospitals | Confidential | No minimum volumes; first orders expected Q4 CY2026 |
Pricing for all commercial products is n/d (commercial-in-confidence).
Financial Detail
Group Entities
| Entity | Country | Ownership | Role |
|---|---|---|---|
Algorae Pharmaceuticals Limited | Australia | Parent | Listed holding company; head office |
AlgoraeRx Pty Ltd | Australia | 100% | Commercial pharmaceuticals (TGA sponsor, sales, distribution) |
Algorae Sciences Pty Ltd | Australia | 100% (new in FY2026) | Science/R&D vehicle (purpose not separately described) |
Living Cell Products Pty Ltd | Australia | 100% | Legacy cell-therapy entity |
Living Cell Technologies New Zealand Ltd | New Zealand | 100% | Legacy NTCELL R&D entity; NZ R&D tax credits |
Revenue by Segment (AUD)
| Segment metric (AUD) | FY2025 | FY2026 |
|---|---|---|
R&D – operating expenses | -825,167 | -1,005,549 |
R&D – R&D tax credits | 737,178 | 384,467 |
R&D – segment result | -72,418 | -621,082 |
Distribution – operating expenses | -59,366 | -697,086 |
Distribution – segment result | -59,366 | -751,704 |
Head Office – interest income | 141,050 | 77,667 |
Head Office – segment result | -794,235 | -1,509,390 |
Eliminations | 123,061 | 171,453 |
Consolidated result | -802,958 | -2,710,723 |
Segment revenue (AUD)
| Segment revenue (AUD) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Research and Development | 0 | 0 | 0 |
Distribution (AlgoraeRx) | 0 | 0 | 0 |
Head Office (interest/other income) | 125,200 | 141,050 | 77,667 |
Segment Overview
| Segment | Total assets (AUD) | Total liabilities (AUD) |
|---|---|---|
Research and Development | 17,760 | 33,472,517 (intercompany) |
Distribution | 409,854 | 1,193,922 (mostly intercompany) |
Head Office | 5,145,244 | 87,229 |
Eliminations | (1,134,803) | (34,576,946) |
Consolidated | 4,438,055 | 176,721 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue and other income (AUD K) | 3.4 | 42.0 | 125.2 | 141.1 | 77.7 |
Of which product/service revenue (AUD K) | 0 | 0 | 0 | 0 | 0 |
Gross profit (AUD K) | 0 | 0 | 0 | 0 | 0 |
Total expenses (AUD K) | — | — | — | 1,696.5 | 3,168.3 |
Operating loss (AUD K) | — | — | — | -1,555.5 | -3,090.6 |
EBITDA (AUD K, ≈ operating loss; no D&A disclosed) | — | — | — | -1,555.5 | -3,090.6 |
Loss before tax (AUD K) | — | — | -2,095.6 | -1,540.1 | -3,095.2 |
Income tax benefit, R&D refund (AUD K) | — | — | 0 | 737.2 | 384.5 |
Net loss (AUD K) | -1,957.3 | -2,107.7 | -2,095.6 | -803.0 | -2,710.7 |
Basic and diluted EPS (A$ cents) | -0.22 | -0.16 | -0.13 | -0.05 | -0.15 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Share price at FYE (AUD) | 0.008 | 0.015 | 0.010 | 0.005 | 0.010 |
Expense line (AUD K)
| Expense line (AUD K) | FY2025 | FY2026 |
|---|---|---|
Research and development | 854.6 | 940.8 |
Distribution (AlgoraeRx) | 0 | 633.2 |
Share-based payments | 35.7 | 490.0 |
Governance (director fees, consultancy, other) | 626.8 | 848.1 |
Administrative | 176.3 | 229.1 |
Borrowing expense | 3.0 | 27.0 |
Total expenses | 1,696.5 | 3,168.3 |
Balance Sheet
| Metric (AUD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Cash at bank | 808.4 | 469.2 | 3,187.3 |
Term deposits | 2,300.0 | 1,850.0 | 750.0 |
Total cash and deposits | 3,108.4 | 2,319.2 | 3,937.3 |
Inventories | 0 | 0 | 180.7 |
Total assets | 3,190 | 2,398.6 | 4,438.1 |
Total liabilities | 176 | 169.8 | 176.7 |
Total debt | 0 | 0 | 0 |
Net debt (negative = net cash) | -3,108.4 | -2,319.2 | -3,937.3 |
Total equity | 3,014.3 | 2,228.8 | 4,261.3 |
Goodwill and intangibles | 0 | 0 | 0 |
Working capital | 3,014 | 2,228.8 | 4,261.3 |
Issued capital | — | 81,540.8 | 85,473.4 |
Accumulated losses | -79,083.6 | -79,885.3 | -82,057.6 |
Cash Flow
| Metric (AUD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | -2,042.2 | -1,986.3 | -1,523.3 | -785.3 | -2,603.9 |
Capex | 0 | 0 | 0 | 0 | 0 |
Free cash flow | -2,042.2 | -1,986.3 | -1,523.3 | -785.3 | -2,603.9 |
Net investing cash flow, term deposits (AUD K) | — | — | — | 450.0 | 1,100.0 |
Net financing cash flow (AUD K) | — | — | — | -3.0 | 4,225.0 |
Equity raised, gross, incl. option exercises (AUD K) | — | — | — | 0 | 4,381.5 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE (%, on average equity) | -30.6 | -83.5 |
ROA (%, on average assets) | -28.7 | -79.3 |
ROIC (%)
| ROIC (%) | n/m | n/m |
|---|---|---|
Current ratio (x) | 14.1 | 25.1 |
Debt / equity (x) | 0 | 0 |
Net debt / EBITDA (x)
| Net debt / EBITDA (x) | n/m | n/m |
|---|---|---|
Interest coverage (x) | n/m | n/m |
Asset turnover (x) | 0 | 0 |
Cash conversion cycle (days) | n/m | n/m |
Region revenue (AUD K)
| Region revenue (AUD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia (interest/other income) | 125.2 | 141.1 | 77.7 |
New Zealand | 0 | 0 | 0 |
Rest of world | 0 | 0 | 0 |
Share Price and Share Count (m)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at FYE (AUD) | 0.008 | 0.015 | 0.010 | 0.005 | 0.010 |
Shares on issue at FYE (m) | — | — | 1,687.4 | 1,687.4 | 2,025.6 |
Market cap at FYE (AUD Mn) | — | — | 16.9 | 8.4 | 20.3 |
Performance Details
| Performance (to 30 Jun 2026, FYE-based) | Return |
|---|---|
1-year | +100% (A$0.005 to A$0.010) |
3-year | -33% (A$0.015 to A$0.010) |
5-year | -17% (A$0.012 on 30 Jun 2021 to A$0.010) |
Long-run | -91% versus A$0.11 at 30 Jun 2017 |
Last verified trade | A$0.013 (24 Jul 2026) |
Valuation Multiples
| Multiple | Algorae | Comment |
|---|---|---|
Market cap | ~A$26.4m | — |
Enterprise value | ~A$22.4m | Market cap less A$3.94m cash and deposits |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | No sales |
P/B | ~6.2x | Book equity A$4.26m |
P/NTA | ~5.4x | NTA 0.24c per share |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None. No major broker coverage (Market Index). |
Dividend history and policy | No dividends ever paid; none expected |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | No debt. The A$3.0m ScotPac facility (24-month term from 20 Jan 2026, expiring ~Jan 2028) is undrawn. |
Outstanding equity instruments | 376,423,855 unlisted options (A$0.014, expiry 1 Dec 2029); 179m performance rights at 30 Jun 2026 (35m lapsed July 2026; 2m converted) |
Liquidity | Highly variable (e.g. 9.7k to 1.8m shares per day in July 2026) |
ASX ranking | ~1,598 of 2,336 ASX companies by market cap (Market Index, when still shown as LCT) |
Analyst Conclusions
Management guidance
No financial guidance has been given. Operational priorities for FY2027 are:
-
TGA submissions across the licensed portfolio.
-
Commencement of supply under commercial agreements, including NSW Health from Q4 CY2026.
-
Completion of the second Peter Mac validation.
-
A shortlist from the multi-anchor AOS2 set.
There are no consensus estimates.
Bull case
-
First revenue imminent. NSW Health orders from Q4 CY2026, capecitabine stock already received and two TGA dossiers in evaluation could deliver Algorae's first product revenue in FY2027. That would allow ScotPac drawdowns and reduce reliance on equity.
-
Option value on the platform. Two independent Peter Mac validations, AOS2 benchmark outperformance and a pool of >6,000 multi-cell-line synergistic combinations offer cheap optionality. An EV of ~A$22m ascribes little value to the platform.
-
Funding pathway in place. Debt-free balance sheet, A$3.9m liquidity, an undrawn A$3m facility and ~A$5.3m of in-the-money-on-recovery options provide a credible bridge. Management incentives are tied to A$10m–A$25m revenue at ≥20% EBIT margin.
Bear case
-
Dilutive pre-revenue spending. Zero product revenue, burn rising to ~A$2.6m+ per year, and governance/admin costs above R&D suggest another raise within 12–18 months at about one cent per share. Shares outstanding already rose 20% in FY2026.
-
Commercial economics unproven. The NSW contract has no volume commitment, ANZ generic margins are thin, and incumbents dominate tenders. Revenue scale relative to the A$10m incentive hurdles is speculative.
-
Pipeline and governance concerns. AI-116 and AI-168 produced no new data in FY2026, NTCELL is dormant, platform claims are not yet peer-reviewed, and governance is concentrated in a three-person board with shared adviser ties and no committees.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Late Oct 2026 | Q1 FY2027 4C: cash balance, burn, first receipts |
| 5 Nov 2026 | AGM: auditor ratification, new incentives, placement capacity |
| Q4 CY2026 | First NSW Health supply orders; first product revenue recognition |
| H2 CY2026 – H1 CY2027 | Outcome of TGA evaluation of first two dossiers; further dossier lodgements (Cadila, Zydus, Torrent Phase 1) |
| ~Sep 2026 – Q1 CY2027 | Full dataset from second Peter Mac validation (AOS2, 24 combinations) |
| H1 CY2027 | Multi-anchor AOS2 shortlist; new patent filings; peer-reviewed publication |
| Ongoing | Capital raising terms; ScotPac drawdown; NTCELL strategic decision; board renewal and independence |
| 27 Feb 2027 (expected) | H1 FY2027 results |
Analyst verdict
Algorae Pharmaceuticals is best understood as a recapitalised shell in the middle of a deliberate reinvention, rather than as a continuation of Living Cell Technologies' decades-long xenotransplantation programme. That legacy consumed roughly A$80m of shareholder capital and left behind tax losses, a dormant Parkinson's implant and a listing.
Since October 2022, a capital-markets-led board has rebuilt the company around two ideas: a low-cost AI combination-synergy platform and a pragmatic ANZ generics sponsor business. FY2026 was the year the second idea became tangible. Five Indian manufacturing partners were signed, a Sandoz- and EBOS-trained commercial team was assembled, two TGA dossiers were accepted, stock was received and a NSW Health supply appointment was won.
The difficulty is that none of this has yet produced a dollar of product revenue. Cash burn tripled to A$2.6m, share-based payments rose sharply and corporate overhead now exceeds R&D spend. The discovery track has produced encouraging but early in-vitro validation and impressive-sounding benchmark numbers. However, the named clinical candidates showed no material progress during the year, and the platform's commercial model (licensing, partnering or internal development) remains undefined.
At roughly A$26m market capitalisation and about A$22m enterprise value, the market is pricing a modest probability that AlgoraeRx becomes a real revenue business, with little value assigned to the AI pipeline. That is not unreasonable. The investment case over the next 12 months is binary on commercial execution. Conversion of NSW Health and TGA milestones into recurring, receivable-backed revenue would de-risk funding, validate management's revenue-linked incentives and give the AI track time to mature. Failure would likely mean further deep-discount dilution.
Assessment: speculative, high-risk, execution-dependent. Monitor quarterly cash flows and first revenue recognition closely. Governance improvements, specifically independent directors and audit and remuneration committees, would materially improve the risk profile.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Qualifications | Independence |
|---|---|---|---|---|---|
David Hainsworth | Executive Chairman (also functions as CEO) | 31 Oct 2022 | 25+ years in capital markets; investment adviser at Euroz Hartleys; Alignment Capital Pty Ltd | BSc | Not independent (executive) |
David Gulland | Non-executive director; also COO of AlgoraeRx (from 23 Mar 2026) | 10 Mar 2026 | Former General Manager, HPS Pharmacies (EBOS Group); 20+ years in hospital pharmacy/medicines supply | MPharm, BSc | Classified non-independent by the board |
Troy Valentine | Non-executive director | 14 Jul 2026 | Chairman, Incannex Healthcare Inc. (Nasdaq: IXHL) since Nov 2023; co-founder of Alignment Capital; ex-Patersons/Canaccord, Hartley Poynton | BCom | Independence n/d; Alignment Capital link suggests limited independence |
Executive Leadership Team
| Name | Role | Since | Background |
|---|---|---|---|
Vishal Shah | Managing Director, AlgoraeRx (initially Chief Commercial Officer) | 30 Jun 2025 | n/d in AR beyond role |
David Gulland | COO, AlgoraeRx | 23 Mar 2026 | See board table |
Waleed Elsayed | Head of Sales | Appointed Mar 2026; commenced Q2 2026 | Former Head of Hospital Sales, Sandoz ANZ |
Dr James McKenna | Chief Scientific Officer | — | Co-supervised Peter Mac validation; leads NTCELL review |
Geraldine Holland and Catherine Earlie | Joint Company Secretaries | 1 Jul 2026 | Replaced Jennifer Voon (stepped down 30 Jun 2026) |
Prof Carolyn Sue | Former CMO (NTCELL) / Medical Advisory Board | ~2019 | Options forfeited FY2025; current role n/d |
Directors' Remuneration
| Person | Cash salary/fees | Bonus | Superannuation | Share-based | Total FY2026 | Total FY2025 |
|---|---|---|---|---|---|---|
David Hainsworth | 232,500 | 0 | 26,400 | 29,182 | 288,082 | 126,879 |
Bradley Dilkes | 50,000 | 0 | 0 | 20,530 | 70,530 | 87,269 |
Bradley Latham | 34,543 | 0 | 0 | 76,012 | 110,555 | 69,522 |
David Gulland | 70,890 | 0 | 6,645 | 9,012 | 86,547 | — |
Vishal Shah | 214,586 | 0 | 24,000 | 27,000 | 265,586 | 56,857 |
Total KMP | 602,519 | 0 | 57,045 | 161,736 | 821,300 | 340,527 |
Major Shareholders
| Holder | Shares | % (approx.) | Source |
|---|---|---|---|
Chunyan Niu | 93,251,315 | 5.53% (at notice; ~4.6% on 30 Jun 2026 share count) | Market Index substantial holder notice 26 Aug 2025 |
Bradley Dilkes and related entities (Cipater, Cichli) | 52,150,000 | ~2.6% | FY2026 AR |
David Hainsworth / Union Square Capital | 25,937,500 | ~1.3% | FY2026 AR |
Bradley Latham | 20,000,000 | ~1.0% | FY2026 AR |
David Gulland / Gull Health | 3,279,333 | ~0.2% | FY2026 AR |
Vishal Shah / Shah Global | 3,166,667 | ~0.2% | FY2026 AR |
Competitive Landscape
Key Competitors
| Competitor | Listing | Positioning versus Algorae |
|---|---|---|
Recursion Pharmaceuticals (merged with Exscientia, 2024) | Nasdaq: RXRX | Scaled phenomics plus AI platform with clinical pipeline; orders of magnitude larger |
Insilico Medicine | Private (Hong Kong IPO activity reported; verify) | End-to-end generative AI; clinical-stage assets |
Schrödinger | Nasdaq: SDGR | Physics-based computational platform with software revenue |
Isomorphic Labs (Alphabet) | Private | Deep-learning structure and drug design; DeepMind's TxGemma was the AOS2 benchmark comparator |
BenevolentAI | Status changed in 2025 (verify) | Knowledge-graph target discovery |
Relay Therapeutics | Nasdaq: RLAY | Computational/structural precision medicine |
Combination-specific academic tools (e.g. DeepSynergy-type models) | Academic | Open models in the same synergy-prediction niche |
Incannex Healthcare | Nasdaq: IXHL | Cannabinoid fixed-dose combinations; shares chair and adviser network |
Alterity Therapeutics | ASX: ATH | Neurodegeneration (MSA); clinical-stage |
Zelira Therapeutics, Bod Science and other ASX cannabinoid-pharma names | ASX | CBD-based therapeutics |
Key Competitors — Sandoz ANZ
| Competitor | Positioning |
|---|---|
Sandoz ANZ | Leading hospital generics/biosimilars; the new Head of Sales came from Sandoz |
Viatris | Broad generics portfolio |
Arrotex Pharmaceuticals | Largest Australian-owned generics company |
Apotex Australia | Major generics supplier |
Juno Pharmaceuticals | Specialty and hospital injectables |
Dr. Reddy's, Sun Pharma, Cipla and other direct ANZ operations | Indian majors with own ANZ subsidiaries |
EBOS Group (HPS) | Distributor/pharmacy services; the COO came from here |
Peer Comparison FY2026
| Metric | Algorae (FY2026) | Top AI-discovery peer | Top ANZ generic peer | Cannabinoid peer |
|---|---|---|---|---|
Revenue (AUD Mn) | 0.0 | n/v | n/v | n/v |
Revenue growth | n/m | n/v | n/v | n/v |
Margins | n/m | n/v | n/v | n/v |
R&D intensity | n/m (A$0.94m absolute) | n/v | n/v | n/v |
Recent Developments
The 2 July 2026 share-price reaction is per the InvestSMART price display (A$0.013 to A$0.010) and should be treated as indicative.



